A higher CD4/CD8 ratio in the tumor microenvironment was also noted in the patient who experienced clinical benefit to the combination with a numerically higher CD4/CD8 ratio in patients with PFS more than 6 months or PR to afatinib/pembrolizumab but was not statistically significant (p = 0.4) with a small sample size (N = 7) (Supplementary Fig. 3). The gene discussed is CD4; the disease is neoplasm.